$ACAD

Needham & Company identified five biotech stocks as top picks for the second half of 2026, all with Buy ratings. Key catalysts include clinical data readouts for Praxia Therapeutics (PRAX), Acadia Pharmaceuticals (ACAD), Biogen (BIIB), Axsome Therapeutics (AXSM), and Alkermes (ALKS). Price targets and analyst upgrades were also noted for these companies.

Acadia Pharmaceuticals (ACAD) received EU approval for DAYBU, its Rett syndrome therapy, marking the first treatment for this condition in the region. The approval, based on positive Phase 3 trial results, expands Acadia's market and may impact its investment narrative. The company projects $1.24–$1.30 billion in 2026 revenue, with DAYBU contributing $480–$510 million. Investors will now focus on pricing, reimbursement, and adoption of DAYBU in Europe.

ACADIA Pharmaceuticals (ACAD) received EU approval for DAYBU, its first treatment for Rett syndrome. The stock has risen 30% in 90 days, but fell 3.7% recently. Analysts suggest a 16% upside to $33.25, citing revenue growth and pipeline momentum, but note risks from R&D spending and clinical trial outcomes.

Acadia Pharmaceuticals (ACAD) received EU approval for DAYBU to treat Rett syndrome, based on Phase 3 trial data. This is the first authorized therapy for Rett syndrome in the EU, potentially opening a new market. The company is now in pricing and reimbursement negotiations. ACAD raised 2026 DAYBU sales guidance to $480M-$510M, with analysts projecting up to $1.9B in revenue. The approval strengthens ACAD's long-term diversification but near-term success depends on country-specific outcomes.

Acadia Pharmaceuticals (NASDAQ:ACAD) reported Q2 2026 total revenues of $308 million, up 17% year over year, driven by DAYBUE and NUPLAZID demand. Management raised 2026 DAYBUE sales guidance to $480 million-$510 million and updated total revenue guidance to $1.24 billion-$1.30 billion. Cash and investments were $956 million as of June 30, 2026.

Acadia Pharmaceuticals said NUPLAZID saw 20% year-over-year growth in new-to-brand prescriptions, and a 40% expansion of its sales force increased targeted providers to about 10,000 to 10,500. For DAYBUE, the STIX formulation drove 60% of June prescriptions, alongside international expansion. Investors are awaiting Phase II remlifanserin Alzheimer’s psychosis data in September or October; Acadia has about $1B cash and is evaluating deals.

Acadia Pharmaceuticals (ACAD) outlined at Canaccord Genuity’s Growth Conference its commercial progress and pipeline. Management said NUPLAZID is at a $700 million annualized sales run rate, with 20% YoY growth in new-to-brand prescriptions, and DAYBUE STIX reached 60% of June prescriptions. Acadia has about $1 billion cash and expects Phase II/III remlifanserin Alzheimer’s disease psychosis data in Sep-Oct 2024.

Acadia Pharmaceuticals shares rose to a 52-week high around $29.76 to $29.81 and were about $29.77 at the time of reporting. The stock is up 36% over six months. Acadia reported Q2 2026 revenue of about $308 million versus a $296 million consensus, driven by Daybue sales of $125 million and steady Nuplazid. RBC, Oppenheimer, and Citizens raised price targets; analysts also cited upward earnings revisions and a Phase 2 RADIANT trial update.

Acadia Pharmaceuticals (ACAD) reported Q2 2026 total revenues of $308 million, up 17% year over year, driven by DAYBUE and NUPLAZID demand. DAYBUE net sales were $125 million (+30%) and NUPLAZID net sales $183 million (+10%). 2026 sales guidance: DAYBUE $480-$510M, NUPLAZID $760-$790M, total revenue $1.24-$1.30B. Net income was $32M ($0.18/share).

Schneyer Mark C. (EVP, CHIEF FINANCIAL OFFICER) sold 20,141 shares of ACADIA PHARMACEUTICALS INC (ACAD) at an average of $29.16 ($29.00–$29.34, $0.59M total) across 3 trades over 2026-08-05 to 2026-08-06 under a Rule 10b5-1 trading plan.